STAG2 and Ewing sarcoma: For example, it has been shown that, STAG2-deficient glioblastoma cells, although not STAG2-deficient Ewing sarcoma cells [24], are more responsive than STAG2 proficient cells to treatment with PARP inhibitors [25].